National Institute on Drug Abuse; Notice of Closed Meetings, 27423-27424 [2020-09924]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 90 / Friday, May 8, 2020 / Notices
The meeting is partially Closed to the
public.
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 4, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: May 5, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09928 Filed 5–7–20; 8:45 am]
[FR Doc. 2020–09917 Filed 5–7–20; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Oncology 1-Basic
Translational Integrated Review Group;
Cancer Genetics Study Section.
Date: June 11–12, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Dr., Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Juraj Bies, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4158, MSC 7806, Bethesda, MD
20892, (301) 435–1256, biesj@mail.nih.gov.
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group; Surgery,
Anesthesiology and Trauma Study Section.
Date: June 11–12, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Dr., Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Weihua Luo, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5114,
MSC 7854, Bethesda, MD 20892, (301) 435–
1170, luow@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
VerDate Sep<11>2014
17:46 May 07, 2020
Jkt 250001
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting. The meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI
Mentored Transition to Independence
Review Committee.
Date: June 10–12, 2020.
Time: 9:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, RKLI,
6705 Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Giuseppe Pintucci, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6705 Rockledge Drive,
Bethesda, MD 20892, 301–435–0287,
Pintuccig@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: May 5, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09921 Filed 5–7–20; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
27423
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; CuttingEdge Basic Research Awards (CEBRA) (R21).
Date: June 1–5, 2020.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neurosciences Center Building, 6001
Executive Boulevard, Rockville, MD 20852
(Virtual Meeting).
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, 6001 Executive Boulevard,
Room 4245, Rockville, MD 20852, (301) 435–
1426, mcguireso@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Assessing the Effects of Cannabinoids on
HIV-Induced Inflammation (R01 Clinical
Trial Optional).
Date: June 10, 2020.
Time: 11:30 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neurosciences Center Building, 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, Division of Extramural
Research, National Institute on Drug Abuse,
NIH, 6001 Executive Boulevard, Room 4238,
MSC 9550, Bethesda, MD 20892, (301) 402–
6020, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIH
Pathway to Independence Award (K99/R00).
Date: June 15, 2020.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neurosciences Center Building, 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
E:\FR\FM\08MYN1.SGM
08MYN1
27424
Federal Register / Vol. 85, No. 90 / Friday, May 8, 2020 / Notices
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, 6001 Executive Boulevard,
Room 4245, Rockville, MD 20852, (301) 435–
1426, mcguireso@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; SEP III:
Step Up for Substance Use Disorders (SUD):
A Drug Target Initiative for Scientists
Engaged in Fundamental Research (U18—
Clinical Trial Not Allowed).
Date: June 16, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neurosciences Center Building, 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Sindhu Kizhakke
Madathil, Ph.D., Scientific Review Officer,
Division of Extramural Research, Scientific
Review Branch, National Institute on Drug
Abuse, NIH, 6001 Executive Boulevard,
Bethesda, MD 20852,
sindhu.kizhakkemadathil@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Notice is
hereby given that, in a letter dated April
3, 2020, the President issued a major
disaster declaration under the authority
of the Robert T. Stafford Disaster Relief
and Emergency Assistance Act, 42
U.S.C. 5121 et seq. (the ‘‘Stafford Act’’),
as follows:
SUPPLEMENTARY INFORMATION:
I have determined that the damage in
certain areas of the State of Oregon resulting
from severe storms, flooding, landslides, and
mudslides during the period of February 5 to
February 9, 2020, is of sufficient severity and
magnitude to warrant a major disaster
declaration under the Robert T. Stafford
Disaster Relief and Emergency Assistance
Act, 42 U.S.C. 5121 et seq. (the ‘‘Stafford
Act’’). Therefore, I declare that such a major
disaster exists in the State of Oregon.
In order to provide Federal assistance, you
are hereby authorized to allocate from funds
available for these purposes such amounts as
you find necessary for Federal disaster
assistance and administrative expenses.
You are authorized to provide Individual
Assistance and Public Assistance in the
designated areas and Hazard Mitigation
throughout the State. Consistent with the
requirement that Federal assistance be
supplemental, any Federal funds provided
under the Stafford Act for Public Assistance,
Hazard Mitigation, and Other Needs
Assistance under section 408 will be limited
to 75 percent of the total eligible costs.
Further, you are authorized to make
changes to this declaration for the approved
assistance to the extent allowable under the
Stafford Act.
97.046, Fire Management Assistance Grant;
97.048, Disaster Housing Assistance to
Individuals and Households In Presidentially
Declared Disaster Areas; 97.049,
Presidentially Declared Disaster Assistance—
Disaster Housing Operations for Individuals
and Households; 97.050, Presidentially
Declared Disaster Assistance to Individuals
and Households—Other Needs; 97.036,
Disaster Grants—Public Assistance
(Presidentially Declared Disasters); 97.039,
Hazard Mitigation Grant.
Pete Gaynor,
Administrator, Federal Emergency
Management Agency.
[FR Doc. 2020–09837 Filed 5–7–20; 8:45 am]
BILLING CODE 9111–23–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Internal Agency Docket No. FEMA–4535–
DR; Docket ID FEMA–2020–0001]
Wyoming; Major Disaster and Related
Determinations
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
AGENCY:
AGENCY:
The time period prescribed for the
implementation of section 310(a),
Priority to Certain Applications for
Public Facility and Public Housing
Assistance, 42 U.S.C. 5153, shall be for
a period not to exceed six months after
the date of this declaration.
The Federal Emergency Management
Agency (FEMA) hereby gives notice that
pursuant to the authority vested in the
Administrator, under Executive Order
12148, as amended, Dolph A. Diemont,
of FEMA is appointed to act as the
Federal Coordinating Officer for this
major disaster.
The following areas of the State of
Oregon have been designated as
adversely affected by this major disaster:
This is a notice of the
Presidential declaration of a major
disaster for the State of Wyoming
(FEMA–4535–DR), dated April 11, 2020,
and related determinations.
DATES: The declaration was issued April
11, 2020.
FOR FURTHER INFORMATION CONTACT:
Dean Webster, Office of Response and
Recovery, Federal Emergency
Management Agency, 500 C Street SW,
Washington, DC 20472, (202) 646–2833.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that, in a letter dated April
11, 2020, the President issued a major
disaster declaration under the authority
of the Robert T. Stafford Disaster Relief
and Emergency Assistance Act, 42
U.S.C. 5121 et seq. (the ‘‘Stafford Act’’),
as follows:
This is a notice of the
Presidential declaration of a major
disaster for the State of Oregon (FEMA–
4519–DR), dated April 3, 2020, and
related determinations.
DATES: The declaration was issued April
3, 2020.
FOR FURTHER INFORMATION CONTACT:
Dean Webster, Office of Response and
Recovery, Federal Emergency
Management Agency, 500 C Street SW,
Washington, DC 20472, (202) 646–2833.
Umatilla County and the Confederated
Tribes of the Umatilla Indian Reservation for
Individual Assistance.
Umatilla, Union, Wallowa Counties and
the Confederated Tribes of the Umatilla
Indian Reservation for Public Assistance.
All areas within the State of Oregon are
eligible for assistance under the Hazard
Mitigation Grant Program.
The following Catalog of Federal Domestic
Assistance Numbers (CFDA) are to be used
for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora
Brown Fund; 97.032, Crisis Counseling;
97.033, Disaster Legal Services; 97.034,
Disaster Unemployment Assistance (DUA);
I have determined that the emergency
conditions in the State of Wyoming resulting
from the Coronavirus Disease 2019 (COVID–
19) pandemic beginning on January 20, 2020,
and continuing, are of sufficient severity and
magnitude to warrant a major disaster
declaration under the Robert T. Stafford
Disaster Relief and Emergency Assistance
Act, 42 U.S.C. 5121 et seq. (the ‘‘Stafford
Act’’). Therefore, I declare that such a major
disaster exists in the State of Wyoming.
In order to provide Federal assistance, you
are hereby authorized to allocate from funds
available for these purposes such amounts as
you find necessary for Federal disaster
assistance and administrative expenses.
Dated: May 4, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09924 Filed 5–7–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Internal Agency Docket No. FEMA–4519–
DR; Docket ID FEMA–2020–0001]
Oregon; Major Disaster and Related
Determinations
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
SUMMARY:
VerDate Sep<11>2014
17:46 May 07, 2020
Jkt 250001
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
SUMMARY:
E:\FR\FM\08MYN1.SGM
08MYN1
]]>Agencies
[Federal Register Volume 85, Number 90 (Friday, May 8, 2020)]
[Notices]
[Pages 27423-27424]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09924]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Cutting-Edge Basic Research Awards (CEBRA) (R21).
Date: June 1-5, 2020.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neurosciences Center
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, NIH, 6001 Executive Boulevard, Room 4245, Rockville, MD
20852, (301) 435-1426, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Assessing the Effects of Cannabinoids on HIV-Induced
Inflammation (R01 Clinical Trial Optional).
Date: June 10, 2020.
Time: 11:30 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neurosciences Center
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892, (301) 402-6020,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIH Pathway to Independence Award (K99/R00).
Date: June 15, 2020.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neurosciences Center
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
[[Page 27424]]
Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, NIH, 6001 Executive Boulevard, Room 4245, Rockville, MD
20852, (301) 435-1426, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; SEP III: Step Up for Substance Use Disorders (SUD):
A Drug Target Initiative for Scientists Engaged in Fundamental
Research (U18--Clinical Trial Not Allowed).
Date: June 16, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neurosciences Center
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific
Review Officer, Division of Extramural Research, Scientific Review
Branch, National Institute on Drug Abuse, NIH, 6001 Executive
Boulevard, Bethesda, MD 20852, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: May 4, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-09924 Filed 5-7-20; 8:45 am]
BILLING CODE 4140-01-P
